Risk factors for non-melanoma skin cancer (NMSC) 1. Skin carcinoma progression analyzed by genome-wide gene expression profiling and mimicked by validated organotypic in vitro human skin cancer models; towards an integrative system-biology approach and an in vitro screening method for targeted skin cancer therapies. 2. Genetic and environmental risk factors for the development of skin cancer in organ-transplant recipients.

Risk factors for non-melanoma skin cancer (NMSC) 1. Skin carcinoma progression analyzed by genome-wide gene expression profiling and mimicked by validated organotypic in vitro human skin cancer models; towards an integrative system-biology approach and an in vitro screening method for targeted skin cancer therapies. 2. Genetic and environmental risk factors for the development of skin cancer in organ-transplant recipients. - Risk factors for non-melanoma skin cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30521

Enrollment

1500

Registered

2007-07-16

Start date

2007-07-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin cancer squamous cell carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Organ-transplant patients and immunocompetent persons with and without skin cancer.

Exclusion criteria

Exclusion criteria: No consent of the patient.

Design outcomes

Primary

Measure	Time frame
Study 1: Firm establishment of consistent shifts in expression profiles of ensembles of genes and/or miRNAs related to certain signaling pathways will provide solid ground for applications for external funding. First, to expand the findings on tumor progression to the proteomic level and enzyme activities. Second, to further refine and explore the potential of newly developed bioinformatical algorithms, e.g. to extract ensembles of activated transcription factors and responsive pathways. In addition, the validated organotypic in vitro human skin cancer models will be used for evaluation of novel therapeutic options, significantly reducing the use of animals for experimentation. Study 2: We will identify genes, which are associated with an increased risk of SCC and/or HPV infection. This will enable us to identify organ-transplant recipients with an increased risk of SCC and/or HPV infection. These data will also be integrated with the results from the genome wide analyses performed in study 1.	—

Measure

Time frame

Study 1: Firm establishment of consistent shifts in expression profiles of ensembles of genes and/or miRNAs related to certain signaling pathways will provide solid ground for applications for external funding. First, to expand the findings on tumor progression to the proteomic level and enzyme activities. Second, to further refine and explore the potential of newly developed bioinformatical algorithms, e.g. to extract ensembles of activated transcription factors and responsive pathways. In addition, the validated organotypic in vitro human skin cancer models will be used for evaluation of novel therapeutic options, significantly reducing the use of animals for experimentation. Study 2: We will identify genes, which are associated with an increased risk of SCC and/or HPV infection. This will enable us to identify organ-transplant recipients with an increased risk of SCC and/or HPV infection. These data will also be integrated with the results from the genome wide analyses performed in study 1.

—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results